Hospitalized patients with COPD or interstitial lung disease are not frequently prescribed opioids for severe breathlessness, and those who are prescribed opioids for breathlessness do not receive timely follow-up.
Among the estimated 166 million US workers, 8 and 7 million had at least 1 asthma-related and at least 1 COPD-related medical event, respectively, between 2011 and 2015.
Children with asthma-like symptoms had double the risk of developing COPD later in life compared to their peers without asthma-like symptoms.
Dysanapsis may be associated with a higher incidence of COPD in older adults.
Nonatopic asthma is associated with adverse outcomes and exacerbation risk in COPD, while patients having atopy alone and atopic asthma had less risk.
Short-term secondhand smoke exposure had a significant effect on pulmonary function in women with asthma, but not in patients with COPD.
Healthcare providers are encountering challenges to treating patients with COPD during the COVID-19 pandemic, but potential solutions are being implemented.
Patients with COPD treated with a metered dose inhaler containing glycopyrrolate and formoterol fumarate had a reduced risk for exacerbations compared with other treatments.
The presence of hypogammaglobulinemia is associated with a higher risk for hospitalization in patients with COPD compared with patients without the condition.
For patients with moderate to severe COPD, dual bronchodilator therapy with a LABA plus a LAMA was found to improve lung function without increasing adverse events.
